Michael Kassirer

Michael Kassirer

Auto-generated profile, based on publicly available information

Michael Kassirer

Pulmonary institute, Soroka university medical center, Beee Sheva, Israel

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2016 in Disaster and Military Medicine
Verified
Journal Article
Open access
PDF file
TBTamar Berger
Tamar Berger
AEArik Eisenkraft
Arik Eisenkraft
EBErez Bar-Haim
Erez Bar-Haim
MKMichael Kassirer
Michael Kassirer
AAAdi Avniel Aran
Adi Avniel Aran
IFItay Fogel
Itay Fogel
Toxins are hazardous biochemical compounds derived from bacteria, fungi, or plants. Some have mechanisms of action and physical properties that make them amenable for use as potential warfare agents. Currently, some toxins are classified as potential biological weapons, although they have several differences from classic living bio-terror pathogens and some similarities to manmade chemical warfare agents. This review focuses on category A and B bio-terror toxins recognized by the Centers for Disease Control and Prevention: Botulinum neurotoxin, staphylococcal enterotoxin B, Clostridium perfringens epsilon toxin, and ricin. Their derivation, pathogenesis, mechanism of action, associated clinical signs and symptoms, diagnosis, and treatment are discussed in detail. Given their expected covert use, the primary diagnostic challenge in toxin exposure is the early detection of morbidity clusters, apart from background morbidity, after a relatively short incubation period. For this reason, it is important that clinicians be familiar with the clinical manifestations of toxins and the appropriate methods of management and countermeasures.

1 September 2014 in Toxicology
Verified
Journal Article
Closed access
SSShai Shrot
Shai Shrot
ERErez Ramaty
Erez Ramaty
YBYoav Biala
Yoav Biala
GBGuy Bar-Klein
Guy Bar-Klein
MDMoshe Daninos
Moshe Daninos
YYYoel Yaari
Yoel Yaari

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
MKMichael Kassirer
Michael Kassirer
NSNitzan Sagie
Nitzan Sagie
MGMichal Gordon
Michal Gordon
BCBracha Cohen
Bracha Cohen
EHEvyatar Bar Haim
Evyatar Bar Haim
YRYael Raviv
Yael Raviv
Background: SABA are the recommended bronchodilator in acute exacerbation of COPD (AECOPD). COPD and cardiovascular disease often coexist. Moreover, the risk of myocardial infarction and stroke increase following AECOPD. Short-acting bronchodilators may exacerbate the adrenergic effects and increase cardiac risk. The aim of this study is to evaluate the safety of SABA in the management of patients with AECOPD and cardiovascular comorbidities. Methods: Data was extracted with MDclone platform from Clalit health services database. All AECOPD hospitalization between 2016 – 2021 were included provided cardiovascular comorbidity was present before hospitalization. Patients were divided into 2 groups: those who receive at least one dose SABA and those who did not. For each subject we matched parallel patient with similar epidemiologic and cardiovascular comorbidities profile. Results: There were 3283 subjects with AECOPD and cardiovascular comorbidities. Patients in the non-SABA group had more ischemic heart disease, CHF, and fewer arrhythmias (75% vs 80%, 62% vs 54%, 23% vs 37%, respectively, p<0.001), After matching, there were 1544 patients in each group. Hospital lenth-of-stay and in-hospital mortality were similar. At 30-days, ther risk of MACE (Major adverse cardiovascular event) was similar in both groups. There was a signal for lower all-cause mortality (4.2 vs 2.9%, p=0.046) in the SABA group. Conclusion: This study demonstrated that SABA did not increase mortality or future cardiovascular risk and was even related with lower 30 days mortality. These data indicate that SABA can be safely given to AECOPD patient with cardiovascular comorbidities.

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
MKMichael Kassirer
Michael Kassirer
NSNitzan Sagie
Nitzan Sagie
MGMichal Gordon
Michal Gordon
BCBracha Cohen
Bracha Cohen
YRYael Raviv
Yael Raviv
Background: COPD exacerbation (AECOPD) are associated with disease progression and impose significant burden on health systems. Respiratory viruses are responsible for one third of AECOPD. RSV vaccines are recommended to individuals over 60 with chronic lung disease. However, the benefit of RSV vaccination in reducing the burden of severe COPD exacerbation is unclear. Thus, we studied the incidence of RSV-infections among hospitalized COPD patients (RSV-AECOPD) Methods: Data was extracted with MDclone platform from 7 hospitals network database. All AECOPD hospitalization between 2018 – 2021 were included provided bacterial infection excluded, and nasal swab PCR test for respiratory viruses completed. For each subject we evaluated risk factors, exacerbation severity, and outcome. We further compared RSV-AECOPD with influenza-AECOPD and all other AECOPD Results: Among 2762 hospitalized AECOPD, 324 (11.8%) tested positive for influenza and 70 (2.6%) tested positive to RSV. Baseline characteristics and comorbidities were comparable between groups. RSV-AECOPD had longer admissions (3.42±3 vs 4.56±3.47 days, p=0.011) and increased need for non-invasive ventilation (19% vs 10%, p=0.037). 30 and 90-days mortality was increased but did not reach statistical significance (2.5 vs 4.4, and 4.9 vs 7.4, respectively, NS). Conclusion: Our data suggest that RSV-AECOPD has worse outcome, but it was relatively uncommon cause of severe AECOPD in our region. These finding emphasize that any vaccination program should consider the expected benefits and expected burden reduction against the resources invested.